Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Compared to best-in-class GLP-1 mono-agonists, unimolecular co-agonists of GLP-1 and GIP with optimized pharmacokinetics enhance glycemic and metabolic benefits in mammals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This was the first human trial to demonstrate that GLP-1R/GCGR co-agonism could be a suitable option for weight loss maintenance, and further, added clinical validation that glucagon agonism could significantly contribute to the regulation of energy balance in an obese setting (Figure 3).”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [85]
In the citing paper
“It acts on GIP receptor five times over GLP-1 receptor [50].”
From The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. (2024) · cites this paper as [50]
In the citing paper
“with preclinical and early-phase clinical trials supporting their potential as next-generation obesity treatments [16–23].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [20]
In the citing paper
“Matthias Tschöp and his team discovered that dual agonists targeting both GLP-1 and GIP receptors (GIPR) are more effective in treating diabetes than those targeting only GLP-1R. These dual agonists were found to reduce blood sugar and increase insulin secretion in mice, monkeys, and humans.27”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [27]
In the citing paper
“a GLP-1/GIP dual agonist produced greater reductions in body weight than GLP-1 monoagonists alone in DIO mice [46, 47, 89].”
From Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes (2024) · cites this paper as [89]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Beige Adipocytes Are a Distinct Type of Thermogenic Fat Cell in Mouse and Human
Wu, J., Boström, P., Sparks, L. M., Ye, L., Choi, J. H., Giang, A.-H., Khandekar, M., Virtanen, K. A., Nuutila, P., Schaart, G., et al. (2012) · Cell · doi:10.1016/j.cell.2012.05.016 · Cited by 3,319
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Self-citationNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 1×
“Finally, preclinical observations with GIPR knockout rodents reported less weight gain on a high-fat diet challenge and an overall protection from glycemic disturbances (6, 7), which was also observed with pharmacological GIP antagonism (9–11) and with transgenic ablation of GIP-producing intestinal K cells (8).”
BackgroundSystematic review and meta-analysis of psychological therapies for children with chronic pain
Fisher, E., Heathcote, L., Palermo, T. M., de C Williams, A. C., Lau, J., & Eccleston, C. (2014) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsu008 · Cited by 710
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Self-citationMiyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454
Peptide YY3–36 and Glucagon-Like Peptide-17–36 Inhibit Food Intake Additively
Neary, N. M., Small, C. J., Druce, M. R., Park, A. J., Ellis, S. M., Semjonous, N. M., Dakin, C. L., Filipsson, K., Wang, F., Kent, A. S., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0237 · Cited by 371
Targeted estrogen delivery reverses the metabolic syndrome
Finan, B., Yang, B., Ottaway, N., Stemmer, K., Müller, T. D., Yi, C.-X., Habegger, K., Schriever, S. C., García-Cáceres, C., Kabra, D. G., et al. (2012) · Nature Medicine · doi:10.1038/nm.3009 · Cited by 337
Self-citationHansotia, T., Baggio, L. L., Delmeire, D., Hinke, S. A., Yamada, Y., Tsukiyama, K., Seino, Y., Holst, J. J., Schuit, F., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1326 · Cited by 309 · cited 1×
“To establish that GLP-1 activity is also present in the co-agonist peptide, we pretreated the GLP-1RKO mice with a GIPR antagonist to generate a GLP-1R and GIPR loss-of-function model, essentially mimicking dual incretin receptor knockout (DIRKO) mice (22).”
MethodSelf-citationTalsania, T., Anini, Y., Siu, S., Drucker, D. J., & Brubaker, P. L. (2005) · Endocrinology · doi:10.1210/en.2005-0473 · Cited by 306
Self-citationA Critical Analysis of the Clinical Use of Incretin-Based Therapies
Butler, P. C., Elashoff, M., Elashoff, R., & Gale, E. A. M. (2013) · Diabetes Care · doi:10.2337/dc12-2713 · Cited by 296
Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure
Hansotia, T., Maida, A., Flock, G., Yamada, Y., Tsukiyama, K., Seino, Y., & Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci25483 · Cited by 290
Self-citationGier, B., Matveyenko, A. V., Kirakossian, D., Dawson, D., Dry, S. M., & Butler, P. C. (2012) · Diabetes · doi:10.2337/db11-1109 · Cited by 255
Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions
Habegger, K. M., Stemmer, K., Cheng, C., Müller, T. D., Heppner, K. M., Ottaway, N., Holland, J., Hembree, J. L., Smiley, D., Gelfanov, V., et al. (2013) · Diabetes · doi:10.2337/db12-1116 · Cited by 245
Self-citationMcClean, P. L., Irwin, N., Cassidy, R. S., Holst, J. J., Gault, V. A., & Flatt, P. R. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00460.2007 · Cited by 239
Vilsbøll, T., Knop, F. K., Krarup, T., Johansen, A., Madsbad, S., Larsen, S., Hansen, T., Pedersen, O., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030738 · Cited by 232
GLP-1 and energy balance: an integrated model of short-term and long-term control
Barrera, J. G., Sandoval, D. A., D'Alessio, D. A., & Seeley, R. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.77 · Cited by 220
Activation of Lipoprotein Lipase by Glucose-dependent Insulinotropic Polypeptide in Adipocytes
Kim, S.-J., Nian, C., & McIntosh, C. H. S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609088200 · Cited by 216
Mentis, N., Vardarli, I., Köthe, L. D., Holst, J. J., Deacon, C. F., Theodorakis, M., Meier, J. J., & Nauck, M. A. (2011) · Diabetes · doi:10.2337/db10-1332 · Cited by 197 · cited 2×
“Additionally, experiments in loss-of-function models for the GLP-1R and GIPR show that the co-agonist does not have the diabetogenic effects of acute glucagon, theweight-lowering effects of chronic glucagon pharmacology, or a glucagon-secretagogue action arising fromGIP agonism (19, 40).”
BackgroundKim, S.-J., Nian, C., Karunakaran, S., Clee, S. M., Isales, C. M., & McIntosh, C. H. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040156 · Cited by 182 · cited 2×
“Likewise, mice treated with GIP analogs (36) or with transgenic GIP overexpression (14) are also protected from diet-induced obesity.”
BackgroundAlthage, M. C., Ford, E. L., Wang, S., Tso, P., Polonsky, K. S., & Wice, B. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710466200 · Cited by 180
Chia, C. W., Carlson, O. D., Kim, W., Shin, Y.-K., Charles, C. P., Kim, H. S., Melvin, D. L., & Egan, J. M. (2009) · Diabetes · doi:10.2337/db08-0958 · Cited by 176
Renner, S., Fehlings, C., Herbach, N., Hofmann, A., von Waldthausen, D. C., Kessler, B., Ulrichs, K., Chodnevskaja, I., Moskalenko, V., Amselgruber, W., et al. (2010) · Diabetes · doi:10.2337/db09-0519 · Cited by 172
Chapter 15 Glucose‐Dependent Insulinotropic Polypeptide (Gastric Inhibitory Polypeptide; GIP)
McIntosh, C. H. S., Widenmaier, S., & Kim, S. (2009) · Vitamins & Hormones · doi:10.1016/s0083-6729(08)00615-8 · Cited by 171
Müller, T. D., Sullivan, L. M., Habegger, K., Yi, C., Kabra, D., Grant, E., Ottaway, N., Krishna, R., Holland, J., Hembree, J., et al. (2012) · Journal of Peptide Science · doi:10.1002/psc.2408 · Cited by 156
Self-citationGault, V. A., O'Harte, F. P. M., Harriott, P., Mooney, M., Green, B., & Flatt, P. R. (2003) · Diabetologia · doi:10.1007/s00125-002-1028-x · Cited by 141
Kim, S.-J., Nian, C., & McIntosh, C. H. S. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m006841 · Cited by 133
Kim, S.-J., Nian, C., & McIntosh, C. H. S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704896200 · Cited by 118
Gault, V. A., O'Harte, F. P. M., Harriott, P., & Flatt, P. R. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6364 · Cited by 108
Widenmaier, S. B., Kim, S.-J., Yang, G. K., De Los Reyes, T., Nian, C., Asadi, A., Seino, Y., Kieffer, T. J., Kwok, Y. N., & McIntosh, C. H. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009590 · Cited by 102
Scrocchi, L. A., & Drucker, D. J. (1998) · Endocrinology · doi:10.1210/endo.139.7.6092 · Cited by 95
Self-citationA randomised , double-blind, placebo-controlled study
Norheim, A. J., Pedersen, E. J., Fø, V., & Berge, L. N. (2001) · Cited by 94
Schelshorn, D. W., Joly, F., Mutel, S., Hampe, C., Breton, B., Mutel, V., & Lütjens, R. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.074757 · Cited by 86
Recent advances in incretin‐based therapies
Russell-Jones, D. L., & Gough, S. C. L. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04483.x · Cited by 83
Faivre, É., Hamilton, A., & Hölscher, C. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.11.007 · Cited by 73
Nauck, M. A., Baranov, O., Ritzel, R. A., & Meier, J. J. (2013) · Diabetologia · doi:10.1007/s00125-013-2953-6 · Cited by 37
An Update in Incretin-Based Therapy: A Focus on Glucagon-Like Peptide-1 Receptor Agonists
Edwards, K. L., Stapleton, M., Weis, J., & Irons, B. K. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0098.edw · Cited by 32
Day, J. W., Li, P., Patterson, J. T., Chabenne, J., Chabenne, M. D., Gelfanov, V. M., & DiMarchi, R. D. (2011) · Journal of Peptide Science · doi:10.1002/psc.1317 · Cited by 23
Self-citationBenardeau, A. M., Verry, P., Atzpodien, E., Funk, J., Meyer, M., Mizrahi, J. L., Winter, M., Wright, M. B., Uhles, S., & ŠEBÖKOVÁ, E. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12006 · Cited by 17
Self-citationGIP: No Longer the Neglected Incretin Twin?
Kulkarni, R. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001027 · Cited by 16
Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis
Amori, R. E., Lau, J., & Pittas, A. G. (2007) · JAMA · doi:10.1001/jama.298.2.194 · Cited by 12
Uhles, S., Wang, H., Benardeau, A. M., Prummer, M., Brecheisen, M., Sewing, S., Tobalina, L., Bosco, D., Wollheim, C. B., Migliorini, C., et al. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01352.x · Cited by 9
Self-citation
Cited by
Peptide therapeutics: current status and future directions
Fosgerau, K., & Hoffmann, T. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.003 · Cited by 3,030
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
“An acylated co-agonist that recognizes both the GLP-1 and GIP receptors produced greater metabolic benefits (glucose control and weight loss) in preclinical studies (including acute studies in non-human primates) relative to GLP-1R agonism alone (Finan et al., 2013).”
BackgroundSelf-citationTherapeutic peptides: Historical perspectives, current development trends, and future directions
Lau, J. L., & Dunn, M. K. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.06.052 · Cited by 1,879
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“Several studies in mice [465,467,685,774] and humans [783e787] have failed to detect changes in energy expenditure following chronic or acute peripheral treatment with different GLP-1R agonists.”
BackgroundSelf-citationGlucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Metadata
- Authors
- Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., Lockie, S. H., Smiley, D. L., Gelfanov, V., Yang, B., Hofmann, S., Bruemmer, D., Drucker, D. J., Pfluger, P. T., Perez-Tilve, D., Gidda, J., Vignati, L., Zhang, L., Hauptman, J. B., Lau, M., Brecheisen, M., Uhles, S., Riboulet, W., Hainaut, E., Sebokova, E., Conde-Knape, K., Konkar, A., DiMarchi, R. D., & Tschöp, M. H.
- Affiliations
- Helmholtz Munich (DE)
- Indiana University Bloomington (US)
- University of Cincinnati (US)
- Karolinska Institutet (SE)
- Monash University (AU)
- Technical University of Munich (DE)
- University of Kentucky (US)
- Mount Sinai Hospital (CA)
- Metabolic Diseases Institute, Division of Endocrinology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45237, USA.
- Marcadia Biotech, Carmel, IN 46032, USA.
- F. Hoffmann-La Roche AG (CH)
- F. Hoffmann–La Roche Ltd., Basel 4070, Switzerland.
- Corresponding author
- Finan, Brian
- Ma, Tao
- DiMarchi, Richard D.
- Tschöp, Matthias H.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2013-10-30
- Volume
- 5
- Issue
- 209
- Pages
- 209ra151-209ra151
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2149717292
- Cited by
- 696
- References
- 44
- Citations by year
- 2026: 46 · 2025: 56 · 2024: 91 · 2023: 71 · 2022: 54 · 2021: 64 · 2020: 56 · 2019: 63 · 2018: 50 · 2017: 40 · 2016: 43 · 2015: 36 · 2014: 22 · 2013: 4
- FWCI
- 27.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Site cant be reached (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, obesity, type 2 diabetes, insulin resistance, fat mass reduction, PEGylation, lipid modification, pharmacokinetics, impaired glucose tolerance, db/db mice, Zucker diabetic fatty rats, Macaca fascicularis, gastrointestinal adverse effects
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Acylation, Adolescent, Adult, Aged, Animals, Haplorhini, Diabetes Mellitus, Type 2, Female, Gastric Inhibitory Polypeptide, Glucose Tolerance Test, Humans, Hyperglycemia, Insulin, Male, Middle Aged, Peptides, Receptors, Gastrointestinal Hormone, Rodentia, Venoms, Weight Loss, Treatment Outcome, Receptors, Glucagon, Mice, Rats, Glucagon-Like Peptide 1, Incretins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.